Ultragenyx Pharmaceutical Inc.
Last 30 daysNo qualifying insider buying. Sales: $17.41K by 1 insider.
Showing the first 6 of 30 trades on this page.
Director
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
SVP, Chief Accounting Officer
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
SVP, Chief Accounting Officer
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
President & CEO
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
President & CEO
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
See Remarks
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
See Remarks
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
See Remarks
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
See Remarks
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
EVP and Chief Legal Officer
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
EVP and Chief Legal Officer
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
EVP & Chief Commercial Officer
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
EVP & Chief Commercial Officer
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
EVP and Chief Medical Officer
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
EVP and Chief Medical Officer
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Chief Financial Officer
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Chief Financial Officer
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common StockGrant or award | 7,751Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units14,058Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Common StockGrant or award10b5-1 | 7,751Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award10b5-1 | Derivative units14,058Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Common StockGrant or award | 7,751Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units14,058Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Common StockGrant or award | 7,751Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units14,058Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Common StockGrant or award | 7,751Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units14,058Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Common StockGrant or award | 7,751Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units14,058Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Common StockGrant or award | 7,751Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units14,058Award · no purchase price | Non-cash award | May 14Filed May 18 · 4d later | SEC filing |
| SVP, Chief Accounting Officer | Common StockGrant or award | 20,241Award · no purchase price | Non-cash award | Apr 22Filed Apr 24 · 2d later | SEC filing |
| SVP, Chief Accounting Officer | Stock Option (Right to Buy)Grant or award | Derivative units7,348Award · no purchase price | Non-cash award | Apr 22Filed Apr 24 · 2d later | SEC filing |
| President & CEO | Common StockGrant or award | 76,745Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| President & CEO | Stock Option (Right to Buy)Grant or award | Derivative units132,693Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| See Remarks | Common StockGrant or award | 23,116Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| See Remarks | Stock Option (Right to Buy)Grant or award | Derivative units79,936Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| See Remarks | Common StockGrant or award | 23,116Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| See Remarks | Stock Option (Right to Buy)Grant or award | Derivative units79,936Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| EVP and Chief Legal Officer | Common StockGrant or award | 28,895Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| EVP and Chief Legal Officer | Stock Option (Right to Buy)Grant or award | Derivative units49,960Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| EVP & Chief Commercial Officer | Common StockGrant or award | 28,895Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| EVP & Chief Commercial Officer | Stock Option (Right to Buy)Grant or award | Derivative units49,960Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| EVP and Chief Medical Officer | Common StockGrant or award | 34,674Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| EVP and Chief Medical Officer | Stock Option (Right to Buy)Grant or award | Derivative units59,952Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| Chief Financial Officer | Common StockGrant or award | 34,674Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
| Chief Financial Officer | Stock Option (Right to Buy)Grant or award | Derivative units59,952Award · no purchase price | Non-cash award | Apr 16Filed Apr 20 · 4d later | SEC filing |
No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
Ultragenyx Pharmaceutical Inc. - Common Stock (RARE) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House memberUltragenyx Pharmaceutical Inc. - Common Stock (RARE) · Stock
The filing reports a purchase for the member.
Gilbert CisnerosReporting House member